Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716878 | 1.00 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1CXCR2ALOX15 | |
| SCHEMBL27157684 | 0.88 | ABCB1 (0.55) | RAB9ASMN1; SMN2NPC1CXCR2POLB | |
| SCHEMBL2999002 | 0.83 | KMT2A (0.46) | RAB9ASMN1; SMN2NPC1ALOX15POLB | |
| SCHEMBL2996508 | 0.83 | HSD17B10 (0.45) | RAB9ASMN1; SMN2NPC1CXCR2ALOX15 | |
| SCHEMBL1620981 | 0.80 | PAK4 (0.49) | RAB9ASMN1; SMN2NPC1ALOX15POLB | |
| SCHEMBL3002685 | 0.80 | METAP2 (0.50) | RAB9ASMN1; SMN2NPC1CXCR2ALOX15 | |
| SCHEMBL3855027 | 0.79 | NPC1 (0.47) | RAB9ASMN1; SMN2NPC1CXCR2HSP90AA1 | |
| SCHEMBL27158283 | 0.78 | CXCR2 (0.43) | RAB9ASMN1; SMN2NPC1CXCR2HSD17B10 | |
| SCHEMBL4408534 | 0.78 | HSP90AA1 (0.39) | RAB9ASMN1; SMN2PIN1HSP90AA1HSD17B10 | |
| SCHEMBL2115655 | 0.78 | PIN1 (0.64) | RAB9ASMN1; SMN2NPC1ALOX15POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4329773-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | Astrocyte Pharmaceuticals, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117241803-A | Purine nucleosides, intermediates and methods of making the same | 阿斯特罗赛特制药公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2022232810-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| CN-101072787-A | Substituted adenines and the use thereof | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | RAB9A 2278/4885SMN1; SMN2 3163/4885NPC1 2463/4885 |
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | NUDT1, PNP, UMPS | RAB9A 3081/4885SMN1; SMN2 293/4885NPC1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.